Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roeland E Wasmann

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2025
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic ModelingMarie Wijk, Roeland E Wasmann, Karen R Jacobson, et al.
British Journal of Clinical Pharmacology|November 17, 2022
Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic modelAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
British Journal of Clinical Pharmacology|December 9, 2020
Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African childrenRoeland E Wasmann, Elin M Svensson, A Sarah Walker, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2022
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with RifampicinAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
European Journal of Clinical Pharmacology|November 18, 2020
Normal fat mass cannot be reliably estimated in typical pharmacokinetic studiesRoeland E Wasmann, Elin M Svensson, Stein J Schalkwijk, et al.
The Journal of Antimicrobial Chemotherapy|February 7, 2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquineAida N Kawuma, Stephen I Walimbwa, Goonaseelan Colin Pillai, et al.
Clinical Pharmacokinetics|August 10, 2017
Clinical Pharmacokinetics and Pharmacodynamics of MicafunginRoeland E Wasmann, Eline W Muilwijk, David M Burger, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2024
Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapyManna Semere Gebreyesus, Roeland E Wasmann, Helen McIlleron, et al.
Journal of the Pediatric Infectious Diseases Society|July 27, 2024
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 TrialHylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, et al.
The Lancet. Child & Adolescent Health|October 22, 2021
One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturationPaolo Denti, Roeland E Wasmann, Jose Francis, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2025
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic ModelingMarie Wijk, Roeland E Wasmann, Karen R Jacobson, et al.
British Journal of Clinical Pharmacology|November 17, 2022
Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic modelAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
British Journal of Clinical Pharmacology|December 9, 2020
Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African childrenRoeland E Wasmann, Elin M Svensson, A Sarah Walker, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2022
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with RifampicinAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
European Journal of Clinical Pharmacology|November 18, 2020
Normal fat mass cannot be reliably estimated in typical pharmacokinetic studiesRoeland E Wasmann, Elin M Svensson, Stein J Schalkwijk, et al.
The Journal of Antimicrobial Chemotherapy|February 7, 2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquineAida N Kawuma, Stephen I Walimbwa, Goonaseelan Colin Pillai, et al.
Clinical Pharmacokinetics|August 10, 2017
Clinical Pharmacokinetics and Pharmacodynamics of MicafunginRoeland E Wasmann, Eline W Muilwijk, David M Burger, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2024
Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapyManna Semere Gebreyesus, Roeland E Wasmann, Helen McIlleron, et al.
Journal of the Pediatric Infectious Diseases Society|July 27, 2024
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 TrialHylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, et al.
The Lancet. Child & Adolescent Health|October 22, 2021
One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturationPaolo Denti, Roeland E Wasmann, Jose Francis, et al.
Pageof 5